Nicole Carolina Sotomayor Páez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Carolina Sotomayor Páez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexander David Silva
Universidad de Las Américas, Quito, Ecuador
1 shared publication - Dario Javier Caguate Miranda
Medical Department, Universidad de las Américas, Quito-Ecuador
1 shared publication - Edgar Felipe Carranza Vargas
Universidad de la Sabana, Bogotá, Colombia
1 shared publication - Gabriela Patricia Guijarro Reinoso
Universidad Técnica de Ambato
1 shared publication - Jonattan Palacios Torres
Médico, Universidad del Sinú, Cartagena de Indias – Colombia
1 shared publication - Norma Susana Chávez Villagómez
Universidad Nacional de Chimborazo
1 shared publication
Latest Publications
- Open Access
- 7 February 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 5, 1417
Optimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches
Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.
- 7 February 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 5, 1417
Open AccessOptimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches
Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.